These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35502922)

  • 1. Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1.
    Gartland M; Cahn P; DeJesus E; Diaz RS; Grossberg R; Kozal M; Kumar P; Molina JM; Mendo Urbina F; Wang M; Du F; Chabria S; Clark A; Garside L; Krystal M; Mannino F; Pierce A; Ackerman P; Lataillade M
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0175121. PubMed ID: 35502922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
    Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C
    Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
    Kozal M; Aberg J; Pialoux G; Cahn P; Thompson M; Molina JM; Grinsztejn B; Diaz R; Castagna A; Kumar P; Latiff G; DeJesus E; Gummel M; Gartland M; Pierce A; Ackerman P; Llamoso C; Lataillade M;
    N Engl J Med; 2020 Mar; 382(13):1232-1243. PubMed ID: 32212519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
    Lataillade M; Zhou N; Joshi SR; Lee S; Stock DA; Hanna GJ; Krystal M;
    J Acquir Immune Defic Syndr; 2018 Mar; 77(3):299-307. PubMed ID: 29206721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1.
    Aberg JA; Shepherd B; Wang M; Madruga JV; Mendo Urbina F; Katlama C; Schrader S; Eron JJ; Kumar PN; Sprinz E; Gartland M; Chabria S; Clark A; Pierce A; Lataillade M; Tenorio AR
    Infect Dis Ther; 2023 Sep; 12(9):2321-2335. PubMed ID: 37751019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1.
    Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M
    Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1.
    Ackerman P; Thompson M; Molina JM; Aberg J; Cassetti I; Kozal M; Castagna A; Martins M; Ramgopal M; Sprinz E; Treviño-Pérez S; Streinu-Cercel A; Latiff GH; Pialoux G; Kumar PN; Wang M; Chabria S; Pierce A; Llamoso C; Lataillade M
    AIDS; 2021 Jun; 35(7):1061-1072. PubMed ID: 33946085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study.
    Llibre JM; Aberg JA; Walmsley S; Velez J; Zala C; Crabtree Ramírez B; Shepherd B; Shah R; Clark A; Tenorio AR; Pierce A; Du F; Li B; Wang M; Chabria S; Warwick-Sanders M
    Front Immunol; 2024; 15():1394644. PubMed ID: 38863717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of clinical envelopes with lack of sensitivity to the HIV-1 inhibitors temsavir and ibalizumab.
    Gartland M; Stewart E; Zhou N; Li Z; Rose R; Beloor J; Clark A; Tenorio AR; Krystal M
    Antiviral Res; 2024 Aug; 228():105957. PubMed ID: 38971430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir.
    Alessandri-Gradt E; Charpentier C; Leoz M; Mourez T; Descamps D; Plantier JC
    J Antimicrob Chemother; 2018 Oct; 73(10):2716-2720. PubMed ID: 30032194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients.
    Saladini F; Giannini A; Giammarino F; Maggiolo F; Vichi F; Corbelli GM; Galli A; Bigoloni A; Poli A; Santoro MM; Zazzi M; Castagna A
    J Antimicrob Chemother; 2020 Sep; 75(9):2547-2553. PubMed ID: 32464638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals.
    Anderson SJ; Murray M; Cella D; Grossberg R; Hagins D; Towner W; Wang M; Clark A; Pierce A; Llamoso C; Ackerman P; Lataillade M
    Patient; 2022 Jan; 15(1):131-143. PubMed ID: 34180035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fostemsavir: a first-in-class HIV-1 attachment inhibitor.
    Grant PM; Kozal MJ
    Curr Opin HIV AIDS; 2022 Jan; 17(1):32-35. PubMed ID: 34871189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients.
    Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure-Response Analysis.
    Lagishetty C; Moore K; Ackerman P; Llamoso C; Magee M
    Clin Transl Sci; 2020 Jul; 13(4):769-776. PubMed ID: 32027457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory Biomarker Reduction With Fostemsavir Over 96 Weeks in Heavily Treatment-Experienced Adults With Multidrug-Resistant HIV-1 in the BRIGHTE Study.
    Clark A; Prakash M; Chabria S; Pierce A; Castillo-Mancilla JR; Wang M; Du F; Tenorio AR
    Open Forum Infect Dis; 2024 Sep; 11(9):ofae469. PubMed ID: 39233711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database.
    Gartland M; Arnoult E; Foley BT; Lataillade M; Ackerman P; Llamoso C; Krystal M
    J Antimicrob Chemother; 2021 Oct; 76(11):2958-2964. PubMed ID: 34297843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
    Thompson M; Lalezari JP; Kaplan R; Pinedo Y; Pena OAS; Cahn P; Stock DA; Joshi SR; Hanna GJ; Lataillade M;
    Antivir Ther; 2017; 22(3):215-223. PubMed ID: 27922453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc.
    Rose R; Gartland M; Li Z; Zhou N; Cockett M; Beloor J; Lataillade M; Ackerman P; Krystal M
    AIDS; 2022 Jan; 36(1):11-18. PubMed ID: 34628442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.